Amarillo, TX – According to filings with the U.S. Securities and Exchange Commission, Ainos, Inc. fka Amarillo Biosciences, Inc. is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Stephen Chen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ainos, Inc. fka Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. (ABI), is a diversified healthcare company engaged in the discovery and development of novel biopharmaceuticals, technologically innovative medical treatments, and specialty consumer products. Our goal is to introduce cutting edge products that actively stimulate and rejuvenate the human body to combat disease and enhance the ability to heal. We are an industry leader in the advancement of low-dose oral interferon as a therapeutic treatment for numerous indications such as thrombocytopenia, Sjogren’s syndrome, hepatitis C virus (HCV) and influenza, a potential multi-million dollar market opportunity. Low-dose oral interferon has been shown to have fewer side effects and is less costly than high-dose injectable interferon. Our management team is seeking global partners to develop a non-toxic and inexpensive low-dose oral formulation of interferon-alpha for the benefit of patients and physicians worldwide.

To learn more about Ainos, Inc. fka Amarillo Biosciences, Inc., visit http://www.amarbio.com/

Contact:
Stephen Chen, Chief Executive Officer
806-376-1741
schen@amarbio.com
https://www.linkedin.com/in/stephen-chen-337210b1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved